Study: Donor stem cells boost survival of patients with high-risk AML

06/9/2009 | Forbes

U.S. researchers found that allogeneic stem cell transplantation, which uses donor stem cells, was more effective than autologous cell transplantation and chemotherapy in improving survival and reducing the risk of relapse in patients with poor and intermediate risk of survival from acute myeloid leukemia. The study suggests that allogeneic transplant could be used as a standard treatment for most patients in the intermediate-risk group, one of the researchers said.

View Full Article in:

Forbes

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Chief Executive Officer
CarePoint Health Plan
Jersey City, NJ
Regional Director, Southeastern Region - State Affairs
America's Heatlh Insurance Plans (AHIP)
Washington, DC
Pharmacy Care Manager
National Association of Chain Drug Stores
Arlington, VA
Senior Director, Research
America's Health Insurance Plans (AHIP)
Washington, DC
Director, Compliance - Health Plan Privacy & Security
Kaiser Permanente
Oakland, CA